American Century Companies Inc. Sells 6,524 Shares of argenex SE $ARGX

Key Points

Error: Response status code does not indicate success: 429 (Too Many Requests).

American Century Companies Inc. lessened its stake in shares of argenex SE (NASDAQ:ARGX - Free Report) by 4.2% in the first quarter, according to its most recent filing with the SEC. The fund owned 148,852 shares of the company's stock after selling 6,524 shares during the period. American Century Companies Inc. owned about 0.24% of argenex worth $88,101,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently modified their holdings of the stock. GeoWealth Management LLC grew its position in argenex by 56.3% during the 4th quarter. GeoWealth Management LLC now owns 50 shares of the company's stock worth $31,000 after purchasing an additional 18 shares in the last quarter. Rakuten Securities Inc. boosted its stake in shares of argenex by 56.4% during the 1st quarter. Rakuten Securities Inc. now owns 61 shares of the company's stock valued at $36,000 after buying an additional 22 shares during the period. Point72 Asia Singapore Pte. Ltd. acquired a new stake in shares of argenex during the 4th quarter valued at $38,000. Golden State Wealth Management LLC acquired a new stake in shares of argenex during the 1st quarter valued at $44,000. Finally, Raiffeisen Bank International AG acquired a new stake in shares of argenex during the 1st quarter valued at $76,000. Institutional investors and hedge funds own 60.32% of the company's stock.

Wall Street Analysts Forecast Growth

ARGX has been the subject of a number of research reports. Robert W. Baird raised shares of argenex from a "neutral" rating to an "outperform" rating and set a $680.00 target price for the company in a research note on Tuesday, May 13th. Guggenheim lifted their price objective on shares of argenex from $1,060.00 to $1,070.00 and gave the company a "buy" rating in a research note on Friday, August 1st. Wedbush reaffirmed an "outperform" rating and issued a $715.00 price objective on shares of argenex in a research note on Monday, July 21st. Citigroup reaffirmed a "buy" rating on shares of argenex in a research note on Wednesday, May 21st. Finally, Baird R W raised shares of argenex from a "hold" rating to a "strong-buy" rating in a research note on Tuesday, May 13th. Two research analysts have rated the stock with a Strong Buy rating and eighteen have given a Buy rating to the company's stock. According to data from MarketBeat, the stock presently has a consensus rating of "Buy" and a consensus price target of $746.81.

argenex Trading Down 0.4%

ARGX traded down $2.46 during trading on Friday, hitting $661.27. The stock had a trading volume of 164,411 shares, compared to its average volume of 373,712. The firm has a market cap of $40.47 billion, a PE ratio of 33.91, a P/E/G ratio of 0.76 and a beta of 0.39. argenex SE has a 12 month low of $510.05 and a 12 month high of $696.21. The company has a 50 day simple moving average of $593.54 and a 200-day simple moving average of $598.04.

argenex (NASDAQ:ARGX - Get Free Report) last announced its earnings results on Thursday, July 31st. The company reported $3.74 EPS for the quarter, topping the consensus estimate of $2.84 by $0.90. The firm had revenue of $866.79 million for the quarter, compared to the consensus estimate of $776.82 million. argenex had a net margin of 40.98% and a return on equity of 21.06%. As a group, sell-side analysts anticipate that argenex SE will post 3.13 earnings per share for the current fiscal year.

argenex Company Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.